Futurity · Health

New mRNA Flu Vaccine Approved for Adults 50+

The FDA has approved Moderna's mFLUSIVA, the first influenza vaccine utilizing mRNA technology, offering a new option for adults aged 50 and older. This development marks a step in evolving flu vaccine technology.

The approval provides a new protection option for older Americans, a demographic disproportionately affected by flu deaths. Current flu vaccine production is lengthy and can lead to mismatches, making faster response times a priority.

Experts consider Moderna's mRNA shot promising, believing mRNA vaccines are the future. Other countries are also reviewing it, with some authorizing a combined mRNA COVID-flu vaccine.

Trials showed mFLUSIVA was ~26.6% more effective than traditional vaccines and elicited a stronger immune response in older adults, with similar rare side effects. Real-world data will be available later.

Unlike traditional vaccines, mRNA vaccines use a genetic script for cells to produce a flu virus component. This platform allows for rapid updates, adapting faster to evolving viral strains.

Infrastructure from the COVID-19 pandemic enables quick production of mRNA flu shots. This could allow vaccines to be updated and ready within months, improving match rates.

Availability and pricing of mFLUSIVA this fall are uncertain, with traditional shots remaining accessible. Uptake may be influenced by public sentiment towards mRNA technology.

While traditional shots remain, mRNA vaccines may take years for younger groups. mFLUSIVA's real-world effectiveness could influence future vaccine development and recommendations.

AI-samenvatting op basis van de bron.